- Home
- MCRB vs VRA Comparison
MCRB vs VRA Comparison
Compare MCRB & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- VRA
- Stock Information
- Founded
- MCRB 2010
- VRA 1982
- Country
- MCRB United States
- VRA United States
- Employees
- MCRB N/A
- VRA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- VRA Apparel
- Sector
- MCRB Health Care
- VRA Consumer Discretionary
- Exchange
- MCRB Nasdaq
- VRA Nasdaq
- Market Cap
- MCRB 72.0M
- VRA 69.2M
- IPO Year
- MCRB 2015
- VRA 2010
- Fundamental
- Price
- MCRB $7.63
- VRA $2.20
- Analyst Decision
- MCRB Hold
- VRA Strong Buy
- Analyst Count
- MCRB 4
- VRA 2
- Target Price
- MCRB $73.67
- VRA $4.00
- AVG Volume (30 Days)
- MCRB 75.0K
- VRA 480.0K
- Earning Date
- MCRB 08-12-2025
- VRA 06-11-2025
- Dividend Yield
- MCRB N/A
- VRA N/A
- EPS Growth
- MCRB N/A
- VRA N/A
- EPS
- MCRB 8.98
- VRA N/A
- Revenue
- MCRB N/A
- VRA $355,671,000.00
- Revenue This Year
- MCRB N/A
- VRA N/A
- Revenue Next Year
- MCRB N/A
- VRA $3.80
- P/E Ratio
- MCRB $0.89
- VRA N/A
- Revenue Growth
- MCRB N/A
- VRA N/A
- 52 Week Low
- MCRB $6.53
- VRA $1.71
- 52 Week High
- MCRB $30.60
- VRA $6.99
- Technical
- Relative Strength Index (RSI)
- MCRB 48.66
- VRA 50.69
- Support Level
- MCRB $7.25
- VRA $2.11
- Resistance Level
- MCRB $7.89
- VRA $2.51
- Average True Range (ATR)
- MCRB 0.46
- VRA 0.24
- MACD
- MCRB 0.11
- VRA 0.00
- Stochastic Oscillator
- MCRB 60.23
- VRA 39.29
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About VRA Vera Bradley Inc.
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.